Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.5050
+0.0166 (3.40%)
At close: Jul 17, 2026, 4:00 PM EDT
0.4667
-0.0383 (-7.58%)
After-hours: Jul 17, 2026, 7:44 PM EDT
Valion Bio Employees
Valion Bio had 52 employees as of December 31, 2025. The number of employees increased by 45 or 642.86% compared to the previous year.
Employees
52
Change (1Y)
45
Growth (1Y)
642.86%
Revenue / Employee
n/a
Profits / Employee
-$265,635
Market Cap
1.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 52 | 45 | 642.86% |
| Dec 31, 2024 | 7 | -2 | -22.22% |
| Dec 31, 2023 | 9 | -7 | -43.75% |
| Jun 30, 2023 | 11 | - | - |
| Dec 31, 2022 | 16 | 9 | 128.57% |
| Dec 31, 2021 | 7 | -1 | -12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Scinai Immunotherapeutics | 45 |
| Calidi Biotherapeutics | 29 |
| VivoSim Labs | 14 |
| Silexion Therapeutics | 14 |
| Azitra | 13 |
| Biodexa Pharmaceuticals | 11 |
| CDT Equity | 4 |
| GRI Bio | 4 |
VBIO News
- 1 day ago - Valion Bio files to sell 29.41M shares of common stock, warrants - TheFly
- 1 day ago - Valion Bio Registration statement: Registration filing - Filings
- 1 day ago - Valion Bio Proxy statement: Proxy filing - Filings
- 4 days ago - Valion Bio reports continued development of Entolimod program - TheFly
- 4 days ago - Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion - PRNewsWire
- 11 days ago - Valion Bio Proxy statement: Proxy filing - Filings
- 23 days ago - AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS - PRNewsWire
- 5 weeks ago - Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures - PRNewsWire